Genprex (NASDAQ:GNPX) Stock Price Up 2.1% – Here’s Why

Genprex (NASDAQ:GNPX) was up 2.1% on Monday . The company traded as high as $0.5369 and last traded at $0.5050. Approximately 270,636 shares were traded during trading, a decline of 29% from the average session volume of 381,310 shares. The stock had previously closed at $0.4948.

Analysts Set New Price Targets

GNPX has been the topic of a number of recent analyst reports. Wall Street Zen raised Genprex from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Genprex presently has an average rating of “Sell”.

Genprex Stock Up 2.9%

The company has a 50 day simple moving average of $0.75 and a 200-day simple moving average of $1.59. The stock has a market cap of $5.84 million, a price-to-earnings ratio of -0.04 and a beta of -0.98.

Genprex (NASDAQ:GNPX) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter.

Institutional Trading of Genprex

A number of institutional investors and hedge funds have recently modified their holdings of GNPX. Manchester Financial Inc. bought a new position in shares of Genprex in the 1st quarter worth about $36,000. Mayflower Financial Advisors LLC bought a new stake in shares of Genprex during the 1st quarter valued at about $36,000. Finally, Susquehanna International Group LLP grew its position in shares of Genprex by 11.7% during the 3rd quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after buying an additional 35,661 shares during the last quarter. 14.05% of the stock is owned by institutional investors and hedge funds.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.